TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02267668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: Physical therapists guide participants through novel set of assigned exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants self-guide through standard exercises
Study: NCT03976583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cpp-Acp
Description: Remineralising agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl powder
Description: Natural product
Study: NCT05913778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Enhanced external counterpulsation
Description: Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
Study: NCT03844958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Furu
Description: 50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Furu
Description: 50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: 50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: 50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day
Study: NCT02107820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT)
Description: All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve stimulation
Description: A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve stimulation
Description: A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each.
Study: NCT04526886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Description: Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
Study: NCT02894437

Intervention type: OTHER
Intervention: qualitative interviews
Description: semi-structured interviews as a conceptual frame work

Intervention type: OTHER
Intervention: qualitative interviews
Description: semi-structured interviews as a conceptual frame work
Study: NCT01560481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 620 mg single dose
Description: metformin glycinate 620 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 1240 mg single dose
Description: metformin glycinate 1240 mg single dose
Study: NCT00429871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study: NCT01560481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 2480 mg single dose
Description: metformin glycinate 2480 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step A: metformin hydrochloride 1000 mg single dose
Description: metformin Chlorhydrate 1000 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 1240 mg,food intake
Description: metformin glycinate 1240 mg, intake of food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step B: metformin glycinate 620 mg BID
Description: metformin glycinate 620 mg BID, 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step B: metformin hydrochloride 500 mg BID
Description: metformin Chlorhydrate 500 mg BID, 8 days
Study: NCT00193427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 1.5 weekly x 7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: To 63 Gy
Study: NCT02572011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Games Console Balance Training
Description: The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
Study: NCT00429871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study: NCT01321853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD2 machine and nurse care coordination
Description: MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medplanner and Nurse Care Coordination
Description: Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
Study: NCT03744702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients will receive IV ascorbic acid.
Study: NCT03480451

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-Disciplinary Patient Centered Rehab and Education
Description: This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being
Study: NCT03187405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVD + IVF with Alteplase
Description: Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
Study: NCT01145963

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control pasta
Description: control pasta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pasta B
Description: experimental pasta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pasta C
Description: experimental pasta
Study: NCT04153695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: to listen flamenco music during 30 minuts per day during 2 weeks
Study: NCT03503396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC Driving Feedback/Warning
Description: Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Feedback
Description: Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
Study: NCT03952767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Physical Measures and Survey Assessments
Description: Data from at home and in clinic visits will assess physical function and survey data will be collected
Study: NCT02867228

Intervention type: OTHER
Group type: OTHER
Intervention: changes in ventilator settings
Description: Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
Study: NCT00375466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
Study: NCT03192137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-305
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 16 days
Study: NCT00622921

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couples-based behavioral psychotherapy
Description: 12 weeks of Couples-based behavioral psychotherapy
Study: NCT02789085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULF TENS stimulation
Study: NCT00418093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
Study: NCT03342937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+Capecitabine+Pembrolizumab
Description: For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.
Study: NCT01079364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed insulin (Insulin Aspart 30/70 )
Description: Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
Study: NCT04590053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
Study: NCT01984736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: EVP-6124
Study: NCT01225120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: 12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
Study: NCT03035994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-Time Biofeedback
Description: A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
Study: NCT02636387

Intervention type: DRUG
Intervention: Desmopressin
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Study: NCT02623205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study: NCT02351960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study: NCT02623205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study: NCT04952051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Folic Acid Tablets Combined With amlodipine
Description: Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Folic Acid Tablets Combined With hydrochlorothiazide
Description: Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
Study: NCT01583985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-intensive prescribing strategy
Description: The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-avoidant prescribing strategy
Description: The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
Study: NCT03182842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre FGM
Description: Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG - Blinded Sensor
Description: Insulin dosing based on SMBG
Study: NCT02905916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT04378257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Guided E-Therapy
Description: The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Therapy
Description: The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
Study: NCT02504177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novel oral anticoagulant for 30 days
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: novel oral anticoagulant for 24 hour
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Study: NCT02097485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w
Description: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Study: NCT02472015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: psycho-behavioural care by telemedicine
Study: NCT03836352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection (q9w)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection (q9w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion (q3w)
Study: NCT01938001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Study: NCT03417193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid free Anesthesia vs Opioid based Anesthesia
Description: Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid free Anesthesia vs Opioid based Anesthesia
Description: Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.